Lynx1 discloses 7.3% C4 Therapeutics (CCCC) ownership stake

Rhea-AI Filing Summary

Lynx1 Capital Management LP and Weston Nichols report a 7.3% beneficial stake in C4 Therapeutics, Inc. common stock, totaling 7,098,133 shares. This percentage is based on 96,914,418 shares outstanding as of October 29, 2025, from the company’s Form 10‑Q for the quarter ended September 30, 2025.

The shares are directly held by Lynx1 Master Fund LP, which has the right to receive dividends and sale proceeds, while Lynx1 Capital Management LP serves as investment manager and Weston Nichols is its control person. The reporting parties certify the holdings were not acquired to change or influence control of C4 Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

C4 Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

12529R107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 12529R107

1

Names of Reporting Persons

Lynx1 Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,098,133.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,098,133.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,098,133.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 12529R107

1

Names of Reporting Persons

Weston Nichols

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,098,133.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,098,133.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,098,133.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: C4 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 490 Arsenal Way, Suite 120, Watertown, MA 02472
Item 2.
(a)	Name of person filing: (i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of C4 Therapeutics, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund; and (ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Lynx1 Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Weston Nichols c/o Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051
(c)	Citizenship: Investment Manager - Delaware Mr. Nichols - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 12529R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 96,914,418 shares of Common Stock outstanding as of October 29, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 6, 2025.
(b)	Percent of class: 7.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lynx1 Capital Management LP

Signature:	/s/ Weston Nichols
Name/Title:	By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Date:	02/17/2026

Weston Nichols

Signature:	/s/ Weston Nichols
Name/Title:	Weston Nichols, Individually
Date:	02/17/2026

FAQ

What ownership stake in C4 Therapeutics (CCCC) does Lynx1 report?

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 7,098,133 C4 Therapeutics common shares, representing 7.3% of the outstanding class. This is calculated using 96,914,418 shares outstanding as of October 29, 2025, from C4’s Form 10‑Q.

Who are the reporting persons in this C4 Therapeutics (CCCC) Schedule 13G/A?

The reporting persons are Lynx1 Capital Management LP, a Delaware limited partnership and investment manager to Lynx1 Master Fund LP, and Weston Nichols, a United States citizen and sole member of Lynx1 Capital Management GP LLC, which controls the investment manager.

How many C4 Therapeutics (CCCC) shares does Lynx1 control voting and disposition for?

Lynx1 Capital Management LP and Weston Nichols report shared voting and dispositive power over 7,098,133 common shares of C4 Therapeutics. They report no sole voting or sole dispositive power over any shares under this Schedule 13G/A.

On what share count is Lynx1’s 7.3% C4 Therapeutics (CCCC) stake based?

The reported 7.3% ownership is calculated using 96,914,418 C4 Therapeutics common shares outstanding as of October 29, 2025. This outstanding share figure comes from the company’s Form 10‑Q for the quarter ended September 30, 2025.

Which entity receives dividends and sale proceeds from Lynx1’s C4 Therapeutics (CCCC) shares?

The filing states that Lynx1 Master Fund LP has the right to receive, or direct the receipt of, dividends and proceeds from the sale of the C4 Therapeutics common shares reported as beneficially owned in this Schedule 13G/A.

Is Lynx1’s C4 Therapeutics (CCCC) position intended to influence control of the company?

The reporting persons certify the C4 Therapeutics shares were not acquired and are not held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a‑11.